Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00070501" target="_blank" >RIV/00216224:14110/13:00070501 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/13:#0002098

Result on the web

<a href="http://dx.doi.org/10.1038/leu.2013.190" target="_blank" >http://dx.doi.org/10.1038/leu.2013.190</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/leu.2013.190" target="_blank" >10.1038/leu.2013.190</a>

Result language

angličtina

Original language name

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

Original language description

Chemoimmunotherapies like the combination of fludarabine, cyclophosphamide, and rituximab (FCR) achieve response rates as high as 95% in patients with previously untreated chronic lymphocytic leukemia (CLL).1 Further improvements in clinical outcome willtherefore mainly depend on attaining more durable remissions in those responders who suffer an early relapse. In general, progression of disease within 24 months after intensive chemoimmunotherapy is regarded as unsatisfactory2 and might be associated with a shortened overall survival.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia

ISSN

0887-6924

e-ISSN

—

Volume of the periodical

27

Issue of the periodical within the volume

9

Country of publishing house

GB - UNITED KINGDOM

Number of pages

4

Pages from-to

1949-1952

UT code for WoS article

000324162700029

EID of the result in the Scopus database

—